The global piriformis syndrome market is expected to gain prominence over the forecast period (2018–2023). It is estimated that the global piriformis syndrome market is expected to register a CAGR of ~ 7.0% during the forecast period of 2018–2023.
Piriformis syndrome is a rare neuromuscular condition that is caused when the piriformis muscle compresses the sciatic nerve. The piriformis muscle is a flat, band-like muscle located in the buttock near the upper region of the hip joint. Piriformis syndrome mostly occurs in adults and can affect individuals from any field and activity levels. The common causes of piriformis syndrome are considered to be trauma, spasms, and overuse injury. Additionally, according to the National Center for Biotechnology Information (NCBI), the piriformis syndrome is more prevalent in patients with pain in the lower back.
The global piriformis syndrome market is majorly driven by the increase in the occurrences of piriformis syndrome, increasing screening, rising safety and success of drug treatments, and the growing geriatric population. The market restraints include the complications of surgeries, lack of awareness about the syndrome, and others. Furthermore, challenges in the diagnosis of the syndrome among the patient pool may hamper the growth of the market.
Company Profiles
- Bayer AG
- Novartis AG
- AstraZeneca
- Endo Pharmaceuticals
- Teva Pharmaceuticals
- Omron Healthcare
- Sanofi S.A.
- DePuy Synthes Companies
- Miracle Stretch, LLC
- Flex Pharma, Inc.
- Nidd valley medical
- SEIRIN Corporation
- Others
Segmentation
The global piriformis syndrome market is segmented on the basis of cause, diagnostic test, treatment, distribution channel, and end-user.
On the basis of cause, the market is classified as trauma, spasms, overuse injury, and others.
The piriformis syndrome market on the basis of diagnostic tests is segmented as Magnetic Resonance Imaging (MRI), X-ray, Computed Tomography (CT), neurophysiologic testing, Electromyography (EMG), Beatty Test, FAIR (Flexion, adduction, and Internal Rotation) test, and others.
On the basis of treatment, the market is segmented into medication, physical therapy, acupuncture, prolotherapy, Osteopathic Manipulative Treatment (OMT), surgery, and others. The medication is further segmented into Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), piriformis muscle injection, and others. NSAIDs are further segmented into naproxen, ibuprofen, and others. Further, the piriformis muscle injection is segmented into Botox injection, steroid injections, and others.
The global piriformis syndrome market, by distribution channel, is segmented into E-commerce, retail pharmacies, and others.
On the basis of end-user, the global piriformis syndrome market is segmented as hospitals and clinics, diagnostic centers, and others.
Global Piriformis Syndrome Market, by Cause
- Trauma
- Spasms
- Overuse injury
- Others
Global Piriformis Syndrome Market, by Diagnostic Test
- Magnetic Resonance Imaging (MRI)
- Computed Tomography (CT)
- X-rays
- Neurophysiologic Testing
- Electromyography (EMG)
- Beatty Test
- FAIR (Flexion, adduction, and Internal Rotation) Test
- Others
Global Piriformis Syndrome Market, by Treatment
- Medication
- NSAIDS
- Naproxen
- Ibuprofen
- Others
- Piriformis Muscle Injection
- Botox Injection
- Steroid Injection
- Others
- Physical Therapy
- Acupuncture
- Prolotherapy
- Osteopathic Manipulative Treatment (OMT)
- Surgery
- Others
Global Piriformis Syndrome Market, by Distribution Channel
- E-Commerce
- Retail Pharmacies
- Others
Global Piriformis Syndrome Market, by End-User
- Hospitals & Clinics
- Diagnostic Centers
- Others
Request Customization
Get a Sample
Get a Sample
Request Customization